Back
Zoetis, Inc. 10K Form
Sell
17
ZTS
Zoetis, Inc.
Last Price:
$120.40
Seasonality Move:
1.97%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2023-11-02 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2023-08-08 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2023-05-04 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2022-11-03 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2022-08-04 | 10Q | ZTS/Zoetis, Inc. Quarterly |
Receive ZTS News And Ratings
See the #1 stock for the next 7 days that we like better than ZTS
ZTS Financial Statistics
Sales & Book Value
| Annual Sales: | $9.3B |
|---|---|
| Cash Flow: | $805M |
| Price / Cash Flow: | 24.46 |
| Annual Sales: | $12.23 |
| Price / Book: | 10.01 |
Profitability
| EPS (TTM): | 5.93500 |
|---|---|
| Net Income (TTM): | $2.7B |
| Gross Margin: | $6.4B |
| Return on Equity: | 52.95% |
| Return on Assets: | 18.33% |
Zoetis, Inc. Earnings Forecast
Key Zoetis, Inc. Financial Ratios
-
The Gross Profit Margin over the past 16 years for ZTS is 69.10%.
-
The Selling, General & Administrative Expenses for ZTS have been equal to 25.04% of Gross Profit Margin.
-
The Research & Development expenses have been 7.41% of Revenue.
-
The Interest Expense is 9.70% of Operating Income.
-
The Net Earning history of ZTS is 26.97% of Total Revenues.
-
Per Share Earnings over the last 16 years have been positive in 14 years.
Zoetis, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | ZTS |
| CUSIP: | 98978V |
| Website: | zoetis.com |
Debt
| Debt-to-Equity Ratio: | 1.35 |
|---|---|
| Current Ratio: | 3.64 |
| Quick Ratio: | 2.02 |
Price-to-Earnings
| Trailing P/E Ratio: | 22.43 |
|---|---|
| Forward P/E Ratio: | 18.04 |
ZTS Technical Analysis vs Fundamental Analysis
Sell
17
Zoetis, Inc. (ZTS)
is a Sell
Is Zoetis, Inc. a Buy or a Sell?
-
Zoetis, Inc. stock is rated a SellThe current Zoetis, Inc. [ZTS] share price is $122.57. The Score for ZTS is 17, which is 66% below its historic median score of 50, and infers higher risk than normal.